Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options
- 9 June 2021
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (14) , 1847-1855
Abstract
The significant morbidity and mortality in patients with heart failure (HF), notably in the most advanced forms of the disease, justify the need for novel therapeutic options. In the last year, the...Keywords
Funding Information
- Content Ed Net France
This publication has 52 references indexed in Scilit:
- The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection FractionJournal of the American Heart Association, 2013
- Riociguat for the Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart diseaseFibrogenesis & Tissue Repair, 2012
- Soluble guanylate cyclase: a potential therapeutic target for heart failureHeart Failure Reviews, 2012
- sGCα1 mediates the negative inotropic effects of NO in cardiac myocytes independent of changes in calcium handlingAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Cardiac TitinCirculation, 2010
- Cyclic GMP signaling in cardiovascular pathophysiology and therapeuticsPharmacology & Therapeutics, 2009
- Hypophosphorylation of the Stiff N2B Titin Isoform Raises Cardiomyocyte Resting Tension in Failing Human MyocardiumCirculation Research, 2009
- Gender-specific hypertension and responsiveness to nitric oxide in sGCα1 knockout miceCardiovascular Research, 2008
- NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNature Reviews Drug Discovery, 2006